当前位置: X-MOL 学术Ther. Adv. Med. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors
Therapeutic Advances in Medical Oncology ( IF 4.3 ) Pub Date : 2019-11-25 , DOI: 10.1177/1758835919890285
Chiara Casadei 1 , Nazli Dizman 2 , Giuseppe Schepisi 1 , Maria Concetta Cursano 3 , Umberto Basso 4 , Daniele Santini 3 , Sumanta K Pal 2 , Ugo De Giorgi 5
Affiliation  

Bladder cancer (BC) is a common cancer worldwide whose incidence has increased in recent years. In Europe, the age-standardized incidence rate of BC is 9.0 for men and 2.2 for women.1 BC can be divided into non-muscle-invasive (NMIBC) and muscle-invasive tumors (MIBC). Approximately 90% of all MIBC are urothelial carcinomas (UC). At diagnosis, 75% of UC are NMIBC, while 25% of cases are MIBC or metastatic disease.2 In an estimated 5–8% of cases, UC originates in the renal pelvis or ureter (upper tract urothelial carcinoma, UTUC).3 Patients with advanced UC are not treatable with curative intent. The first-line standard of care is cisplatin-containing chemotherapy such as gemcitabine-cisplatin or M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin), both of which are characterized by similar efficacy but with a better safety profile for the former.4,5 However, about 30% of patients are not candidates for cisplatin due to renal dysfunction, poor performance status (PS), or other comorbidities.6 Alternative chemotherapeutic regimens, such as carboplatin-based therapies, correlate with inferior outcomes.7,8 Traditionally, the median overall survival (OS) ranged between 14 and 16 months in patients with advanced UC treated with platinum-based regimens, and long-term survival was rare.2,4

中文翻译:


晚期膀胱癌的靶向治疗:FGFR 抑制剂的新策略



膀胱癌(BC)是世界范围内的常见癌症,近年来发病率有所上升。在欧洲,BC 的年龄标准化发病率为男性 9.0,女性 2.2。 1 BC可分为非肌层浸润性肿瘤(NMIBC)和肌层浸润性肿瘤(MIBC)。大约 90% 的 MIBC 是尿路上皮癌 (UC)。诊断时,75% 的 UC 为 NMIBC,而 25% 的病例为 MIBC 或转移性疾病。 2估计 5-8% 的病例中,UC 起源于肾盂或输尿管(上尿路尿路上皮癌,UTUC)。 3晚期 UC 患者无法进行根治性治疗。一线标准治疗是含顺铂的化疗,例如吉西他滨-顺铂或 M-VAC(甲氨蝶呤、长春花碱、阿霉素和顺铂),两者的疗效相似,但前者的安全性更好。 4,5然而,约 30% 的患者由于肾功能障碍、体能状态 (PS) 或其他合并症而不适合顺铂。 6替代化疗方案(例如基于卡铂的疗法)与较差的结果相关。 7,8传统上,接受含铂方案治疗的晚期 UC 患者的中位总生存期 (OS) 为 14 至 16 个月,且长期生存很少见。 2,4
更新日期:2019-11-25
down
wechat
bug